Cargando…
GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment
Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674369/ https://www.ncbi.nlm.nih.gov/pubmed/23681232 http://dx.doi.org/10.1038/cddis.2013.162 |
_version_ | 1782272363079925760 |
---|---|
author | Yu, Y Huang, H Li, J Zhang, J Gao, J Lu, B Huang, C |
author_facet | Yu, Y Huang, H Li, J Zhang, J Gao, J Lu, B Huang, C |
author_sort | Yu, Y |
collection | PubMed |
description | Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found that p53 protein expression was upregulated in GADD45β−/− cells upon arsenite exposure as compared with those in GADD45β+/+ cells. Further studies showed that GADD45β attenuated p53 protein expression through Src/protein phosphatase 2A/murine double minute 2-dependent p53 protein-degradation pathway. Moreover, we identified that GADD45β-mediated p53 protein degradation was crucial for its anti-apoptotic effect due to arsenite exposure, whereas increased JNK activation was not involved in the increased cell apoptotic response in GADD45β−/− cells under same experimental conditions. Collectively, our results demonstrate a novel molecular mechanism responsible for GADD45β protection of arsenite-exposed cells from cell death, which provides insight into our understanding of GADD45β function and a unique compound arsenite as both a cancer therapeutic reagent and an environmental carcinogen. Those novel findings may also enable us to design more effective strategies for utilization of arsenite for the treatment of cancers. |
format | Online Article Text |
id | pubmed-3674369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36743692013-06-06 GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment Yu, Y Huang, H Li, J Zhang, J Gao, J Lu, B Huang, C Cell Death Dis Original Article Growth arrest and DNA-damage-inducible, beta (GADD45β) has been reported to inhibit apoptosis via attenuating c-Jun N-terminal kinase (JNK) activation. We demonstrated here that GADD45β mediated its anti-apoptotic effect via promoting p53 protein degradation following arsenite treatment. We found that p53 protein expression was upregulated in GADD45β−/− cells upon arsenite exposure as compared with those in GADD45β+/+ cells. Further studies showed that GADD45β attenuated p53 protein expression through Src/protein phosphatase 2A/murine double minute 2-dependent p53 protein-degradation pathway. Moreover, we identified that GADD45β-mediated p53 protein degradation was crucial for its anti-apoptotic effect due to arsenite exposure, whereas increased JNK activation was not involved in the increased cell apoptotic response in GADD45β−/− cells under same experimental conditions. Collectively, our results demonstrate a novel molecular mechanism responsible for GADD45β protection of arsenite-exposed cells from cell death, which provides insight into our understanding of GADD45β function and a unique compound arsenite as both a cancer therapeutic reagent and an environmental carcinogen. Those novel findings may also enable us to design more effective strategies for utilization of arsenite for the treatment of cancers. Nature Publishing Group 2013-05 2013-05-16 /pmc/articles/PMC3674369/ /pubmed/23681232 http://dx.doi.org/10.1038/cddis.2013.162 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article Yu, Y Huang, H Li, J Zhang, J Gao, J Lu, B Huang, C GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title | GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title_full | GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title_fullStr | GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title_full_unstemmed | GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title_short | GADD45β mediates p53 protein degradation via Src/PP2A/MDM2 pathway upon arsenite treatment |
title_sort | gadd45β mediates p53 protein degradation via src/pp2a/mdm2 pathway upon arsenite treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674369/ https://www.ncbi.nlm.nih.gov/pubmed/23681232 http://dx.doi.org/10.1038/cddis.2013.162 |
work_keys_str_mv | AT yuy gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT huangh gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT lij gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT zhangj gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT gaoj gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT lub gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment AT huangc gadd45bmediatesp53proteindegradationviasrcpp2amdm2pathwayuponarsenitetreatment |